EMEA-001555-PIP01-13-M03

Key facts

Invented name
Xerava
Active substance
eravacycline
Therapeutic area
Infectious diseases
Decision number
P/0251/2019
PIP number
EMEA-001555-PIP01-13-M03
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of complicated intra-abdominal infection
Route(s) of administration
Intravenous use
Contact for public enquiries
Tetraphase Pharmaceuticals, Inc.

Tel. +1 617 7153600
E-mail: regaffairs@tphase.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating